Desarrollo de nuevas vacunas frente al virus del papiloma humano

Rodríguez-Cerdeira, Carmen; Menéndez, Alfonso Alba; Corell, Juan José Vilata

doi:10.1016/s0213-9251(07)73014-9

Cited by 6 publications

(2 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…And furthermore, we would like to emphasise that the increasing incidence of HPV infection and genital warts highlights the need for an effective strategy for the management of this disease. Finally, immunisation holds the promise of reducing the overall load of clinical HPV-related diseases [47]. Fig.…”

Section: Real-time Pcrmentioning

confidence: 99%

The Human Papillomavirus (HPV) in Human Pathology: Description, Pathogenesis, Oncogenic Role, Epidemiology and Detection Techniques

Alba¹,

Cararach²,

Rodríguez-Cerdeira³

2009

TODJ

View full text Add to dashboard Cite

Persistent infection by human papilloma virus (HPV) is considered to be the main causative agent of cervical cancer and other anogenital cancers. Of more than 30 genotypes capable of infecting the anogenital tract it is estimated that, worldwide, HPV 16 and 18 cause 70 percent of the cervical cancers. So far, more than 100 types and subtypes of HPVs have been wholly or partially sequenced. All of them, approximately 40 types, have been isolated from lesions to the lower genital tract and between 15 and 20, according to different studies, have been detected in carcinomas. According to their oncogenic risk, they are classified as low-risk HPV (LR-HPV) and high-risk HPV (HR-HPV). We must take into account that certain viral types may appear in cancerous lesions as a result of a co-infection and not be the causative etiologic agents for tumour transformation. As is logical, epidemiological studies attribute important population variations to the prevalence and cause/effect of different viral types, however, there is no doubt about the high prevalence or involvement of types 16 and 18 in high level pathologies and carcinomas in our population. The detection of HPV DNA through techniques of Molecular Biology, regardless of the method used, are based on the specificity of the complementarity among the nucleic acids. A DNA sequence has the ability to specifically hybridise with other DNAs or RNAs so specifically that at a certain temperature they only form hybrids if 100 percent of the bases are complementary. The way of detecting these hybrids, the composition of the DNA probes, and the existence or not of amplification of the signal mark the difference between the different detection techniques. The assessment of the viral load, integration, and other molecular parameters are shaping up as excellent complementary diagnoses in daily clinical practice.

show abstract

Section: Real-time Pcrmentioning

confidence: 99%

The Human Papillomavirus (HPV) in Human Pathology: Description, Pathogenesis, Oncogenic Role, Epidemiology and Detection Techniques

Alba¹,

Cararach²,

Rodríguez-Cerdeira³

2009

TODJ

View full text Add to dashboard Cite

show abstract

“…There is a very good safety profile for both vaccines within the age range evaluated in the tests 15-26 years old, and for the follow-up time available. This safety profile has been ratified until present with after sales vigilance, after the administration of millions of doses of Gardasil ® and Cervarix ® throughout the world [12,13].…”

Section: Prophylactic Vaccines Against Hpv Infectionmentioning

confidence: 99%

Vaccines for Papillomavirus (HPV) Infection

Rodríguez-Cerdeira¹,

Alba²

2009

TODJ

View full text Add to dashboard Cite

Prophylactic HPV vaccination of both quadrivalent and bivalent vaccines has already been approved in Spain and is gaining popularity among Spanish women. Other European countries show similar trends.With the use of vaccines against HPV, especially the tetravalent vaccine, in the short or medium-term there will be a lower rate of abnormal cytological results in vaccinated women, which is based on the expected preventive potential, which may range between 50 to 70% of the cases. Furthermore, with the use of the vaccine, in combination with present screening programs, we expect to reach a 92% reduction in the annual number of cases of cervical cancer and other associated pathologies in our country.

show abstract